Anna Rodina, PhD

Senior Research Scientist
Anna Rodina, PhD

Lab Phone


My research interests are broad and include areas in basic and translational oncology. I have an extensive background in cancer biology and biochemistry with a specific training and expertise in evaluation of chemical tools in in vitro and in vivo systems. Being at Memorial Sloan Kettering Cancer Center, I have extended my expertise to drug discovery by developing selectivity- and phenotypical assays for chaperome inhibitors and studying chaperome biology in cancer and neurodegenerative diseases using these tools. My efforts have resulted in multiple publications and patent applications.

My major focus is to study the biochemical and functional mechanism behind the epichaperome, and to investigate the translational significance of epichaperome multi-protein complexes in cancer. Towards this goal, I studied the mechanisms associated with epichaperome complex formation and its role in the sensitivity of tumors to HSP90 inhibitors. Specifically, I have developed methods to identify and characterize the epichaperome complex.

Another way to inhibit epichaperome networks in cancer is through targeting HSP70. Towards this goal we have discovered an inhibitor of a previously unknown allosteric HSP70 site, YK5. Derivatives of this compound have been made by my chemistry colleagues to identify those that are potent and selective binders of HSP70 epichaperomes. This generation of inhibitors represents a viable starting point for the development of novel anticancer therapeutics. High potency agents are now on the way to clinical translation. I am deeply involved in the investigation of these agents, of their mechanism of action and in the development of strategies for their rational translation to clinic.



  1. Inda MC, Joshi S, Wang T, Bolaender A, Gandu S, Koren Iii J, Che AY, Taldone T, Yan P, Sun W, Uddin M, Panchal P, Riolo M, Shah S, Barlas A, Xu K, Chan LYL, Gruzinova A, Kishinevsky S, Studer L, Fossati V, Noggle SA, White JR, de Stanchina E, Sequeira S, Anthoney KH, Steele JW, Manova-Todorova K, Patil S, Dunphy MP, Pillarsetty N, Pereira AC, Erdjument-Bromage H, Neubert TA, Rodina A, Ginsberg SD, De Marco Garcia N, Luo W, Chiosis G. The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction. Nat Commun. 2020 Jan 16;11(1):319.
  2. Taldone T, Wang T, Rodina A, Pillarsetty NVK, Digwal CS, Sharma S, Yan P, Joshi S, Pagare PP, Bolaender A, Roboz GJ, Guzman ML, Chiosis G. A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond. Cold Spring Harb Perspect Biol. 2020 Apr 1;12(4).
  3. Kishinevsky S, Wang T, Rodina A, Chung SY, Xu C, Philip J, Taldone T, Joshi S, Alpaugh ML, Bolaender A, Gutbier S, Sandhu D, Fattahi F, Zimmer B, Shah SK, Chang E, Inda C, Koren J 3rd, Saurat NG, Leist M, Gross SS, Seshan VE, Klein C, Tomishima MJ, Erdjument-Bromage H, Neubert TA, Henrickson RC, Chiosis G, Studer L. HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons. Nat Commun. 2018 Oct 19;9(1):4345.
  4. Rodina AWang TYan PGomes EDDunphy MPPillarsetty NKoren JGerecitano JFTaldone TZong HCaldas-Lopes EAlpaugh MCorben ARiolo MBeattie BPressl CPeter RIXu CTrondl RPatel HJShimizu FBolaender AYang CPanchal PFarooq MFKishinevsky SModi SLin OChu FPatil SErdjument-Bromage HZanzonico PHudis CStuder LRoboz GJCesarman ECerchietti LLevine RMelnick ALarson SMLewis JSGuzman MLChiosis G. The epichaperome is an integrated chaperome that facilitates tumour survival. Nature. 2016 Oct 20;538(7625):397-401.
  5. Rodina A, Taldone T, Kang Y, Patel PD, Koren J 3rd, Yan P, DaGama Gomes EM, Yang C, Patel MR, Shrestha L, Ochiana SO, Santarossa C, Maharaj R, Gozman A, Cox MB, Erdjument-Bromage H, Hendrickson RC, Cerchietti L, Melnick A, Guzman ML, Chiosis G. Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer. ACS Chem Biol. 2014 Aug 15;9(8):1698-705.
  6. Rodina A, Patel PD, Kang Y, Patel Y, Baaklini I, Wong M, Taldone T, Yan P, Yang C, Maharaj R, Gozman A, Patel M, Patel H,  Erdjument-Bromage H, Talele T, Young JC and Chiosis G. Identification of an allosteric pocket on human Hsp70 reveals a novel mode of inhibition of this therapeutically important protein . Chemistry and Biology 2013 Dec 19;20(12):1469-80.
  7. Taldone T, Rodina A, Dagama Gomes EM, Riolo M, Patel HJ, Alonso-Sabadell R, Zatorska D, Patel MR, Kishinevsky S, Chiosis G. Synthesis and evaluation of cell-permeable biotinylated PU-H71 derivatives as tumor Hsp90 probes. Beilstein J Org Chem. 2013 Mar 15;9:544-56.
  8. Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama E, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, Alpaugh M, Gross SS, Pillarsetty N, Ku T, Lewis JS, Larson SM, Levine R, Erdjument-Bromage H, Guzman M, Nimer SD, Melnick A, Neckers L, Chiosis G. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature Chem Biol 2011, 7(11):818-26.
  9. Rodina A, Vilenchik M, Moulick K, Aguirre J, Kim J, Chiang A, Litz J, Clement C, Kang Y, She Y, Wu N, Felts S, Wipf P, Massague J, Jiang X, Brodsky J, Krystal G and Chiosis G. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nature Chem Biol 2007; 3(8):498-507.
  10. Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard P and Chiosis G. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. PNAS 2007; 104(22):9511-9516.